A phase I clinical trial evaluated intrathecal administration of dual-target CAR-T cells directed against two glioblastoma-associated antigens: epidermal growth factor receptor (EGFR) and interleukin 13 receptor α2 (IL13Rα2). This evidence concerns the gene IL13RA2 and glioblastoma.